Reduced expression levels of let‑7c in human breast cancer patients

Li,Xin‑Xin; Gao,Shu‑Yan; Wang,Ping‑Yu; Zhou,Xue; Li,You‑Jie; Yu,Yuan; Yan,Yun‑Fei; Zhang,Han‑Han; Lv,Chang‑Jun; Zhou,Hui‑Hui; Xie,Shu‑Yang

doi:10.3892/ol.2015.2877

Reduced expression levels of let‑7c in human breast cancer patients

Authors:
- Xin‑Xin Li
- Shu‑Yan Gao
- Ping‑Yu Wang
- Xue Zhou
- You‑Jie Li
- Yuan Yu
- Yun‑Fei Yan
- Han‑Han Zhang
- Chang‑Jun Lv
- Hui‑Hui Zhou
- Shu‑Yang Xie
View Affiliations

Affiliations: Key Laboratory of Tumor Molecular Biology, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Shandong 264003, P.R. China, Department of Clinical Medicine, Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Department of Pathology, Affiliated Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: January 14, 2015 https://doi.org/10.3892/ol.2015.2877
Pages: 1207-1212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating microRNAs (miRNAs) are important in the diagnosis of a number of diseases, since serum or plasma miRNAs are more stable compared with miRNA isolated from blood samples. The aim of the present study was to investigate the association between the expression levels of serum let‑7c miRNA and the clinical diagnosis of breast cancer (BC). The circulating let‑7c levels of 90 BC patients and 64 healthy controls were determined by performing a reverse transcription‑quantitative polymerase chain reaction assay. The results demonstrated that let‑7c expression was downregulated in the BC tissues compared with the paracarcinoma control tissues. In addition, the let‑7c expression in the serum of BC patients was significantly lower compared with the healthy controls (P<0.01). Using a cutoff value of 0.374x103 copies/ml, the serum expression levels of let‑7c exhibited 87.5% sensitivity and 78.9% specificity for distinguishing BC patients from healthy controls (area under the receiver operating characteristic curve, 0.848; 95% confidence interval, 0.785‑0.911). Furthermore, the results demonstrated that the serum expression levels of let‑7c were significantly higher in premenopausal compared with postmenopausal patients (P<0.05), supporting the hypothesis that postmenopausal status may affect the serum expression levels of let‑7c. However, no statistically significant differences were detected in the serum levels of let‑7c between ER (or PR)‑positive and ‑negative patients. Therefore, the current study hypothesized that serum let‑7c may be used as a novel and valuable biomarker for the diagnosis of BC.

View Figures

View References

1	Asaga S, Kuo C, Nguyen T, et al: Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 57:84–91. 2011. View Article : Google Scholar
2	Heneghan HM, Miller N, Lowery AJ, et al: MicroRNAs as novel biomarkers for breast cancer. J Oncol. 2009:9502012009.PubMed/NCBI
3	Roth C, Rack B, Müller V, et al: Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12:R902010. View Article : Google Scholar : PubMed/NCBI
4	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar
5	Zhao B, Han H, Chen J, et al: MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 342:43–51. 2014. View Article : Google Scholar
6	Sempere LF, Freemantle S, Pitha-Rowe I, et al: Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 5:R132004. View Article : Google Scholar : PubMed/NCBI
7	Pelosi A, Careccia S, Lulli V, et al: miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene. 32:3648–3654. 2013. View Article : Google Scholar
8	Qian B, Katsaros D, Lu L, et al: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 117:131–140. 2009. View Article : Google Scholar
9	Wang PY, Sun YX, Zhang S, et al: Let-7c inhibits A549 cell proliferation through oncogenic TRIB2 related factors. FEBS Lett. 587:2675–2681. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wu Q, Wang C, Lu Z, Guo L and Ge Q: Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta. 413:1058–1065. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zhang HH, Pang M, Dong W, et al: miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 31:1473–1479. 2014.PubMed/NCBI
13	Wang PY, Sun YX, Zhang S, et al: Let-7c inhibits A549 cell proliferation through oncogenic TRIB2 related factors. FEBS Lett. 587:2675–2681. 2013. View Article : Google Scholar : PubMed/NCBI
14	Hu X, Guo J, Zheng L, et al: The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res. 11:240–250. 2013. View Article : Google Scholar : PubMed/NCBI
15	Piskounova E, Polytarchou C, Thornton JE, et al: Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 147:1066–1079. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 23:7721–7735. 2005. View Article : Google Scholar : PubMed/NCBI
17	Diaz NM: Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control. 8:415–418. 2001.PubMed/NCBI
18	Kerlikowske K, Cook AJ, Buist DS, et al: Breast cancer risk by breast density, menopause and postmenopausal hormone therapy use. J Clin Oncol. 28:3830–3837. 2010. View Article : Google Scholar : PubMed/NCBI
19	Qin B, Xiao B, Liang D, et al: MicroRNA let-7c inhibits Bcl-xl expression and regulates ox-LDL-induced endothelial apoptosis. BMB Rep. 45:464–469. 2012. View Article : Google Scholar : PubMed/NCBI
20	Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell. 120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jones CI, Zabolotskaya MV, King AJ, et al: Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 107:1987–1996. 2012. View Article : Google Scholar : PubMed/NCBI
22	Sakurai M, Miki Y, Masuda M, et al: LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol. 131:101–106. 2012. View Article : Google Scholar
23	Zhu XM, Wu LJ, Xu J, Yang R and Wu FS: Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res. 39:2323–2329. 2011. View Article : Google Scholar
24	Shimizu S, Takehara T, Hikita H, et al: The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 52:698–704. 2010. View Article : Google Scholar : PubMed/NCBI
25	Björner S, Fitzpatrick PA, Li Y, et al: Epithelial and stromal microRNA signatures of columnar cell hyperplasia linking Let-7c to precancerous and cancerous breast cancer cell proliferation. PLoS One. 9:e1050992014. View Article : Google Scholar : PubMed/NCBI
26	Barnes DM and Hanby AM: Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology. 38:271–274. 2001. View Article : Google Scholar : PubMed/NCBI
27	Sofi GN, Sofi JN, Nadeem R, et al: Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev. 13:5047–5052. 2012. View Article : Google Scholar : PubMed/NCBI
28	Faheem M, Mahmood H, Khurram M, Qasim U and Irfan J: Estrogen receptor, progesterone receptor and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience. 6:2832012.